Tobira Therapeutics Inc. Presents Positive Phase 2b Clinical Results for Cenicriviroc in Treatment-Naïve HIV Infection in Late Breaker Session at CROI
3/5/2013 1:49:37 PM
More...
|
Tobira Therapeutics Inc. Announces Positive 24-Week Primary Analysis From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection
1/7/2013 10:30:05 AM
More...
|
Tobira Therapeutics Inc. to Present at the 31st Annual J. P. Morgan Healthcare Conference
12/19/2012 7:12:07 AM
More...
|
Tobira Therapeutics Inc. Receives Additional US Patent on Cenicriviroc
10/26/2012 7:37:09 AM
More...
|
Tobira Therapeutics Inc. Completes Senior Management Team With Key Strategic Hires in Finance, Clinical and Pharmaceutical Sciences
9/10/2012 9:12:06 AM
More...
|
Antoun Nabhan, JD, Joins Tobira Therapeutics Inc. Leadership Team
4/5/2012 10:14:49 AM
More...
|
Tobira Therapeutics Inc. Continues Management Team Expansion
1/5/2012 7:00:54 AM
More...
|
Tobira Therapeutics Inc. Announces Key Management Team Additions
8/8/2011 10:03:11 AM
More...
|
Tobira Therapeutics Inc. Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults
7/19/2011 9:12:22 AM
More...
|
Tobira Therapeutics Inc. Initiates Phase IIb Trial of Cenicriviroc, a Novel CCR5/CCR2 Antagonist for the Treatment of HIV Infection
6/22/2011 8:48:22 AM
More...
|
|